Zacks Research Has Positive Outlook for TEVA Q1 Earnings

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) - Investment analysts at Zacks Research boosted their Q1 2026 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a note issued to investors on Wednesday, June 25th. Zacks Research analyst R. Department now forecasts that the company will earn $0.49 per share for the quarter, up from their previous forecast of $0.48. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' FY2026 earnings at $2.61 EPS, Q1 2027 earnings at $0.65 EPS and FY2027 earnings at $2.81 EPS.

Several other equities research analysts have also commented on the stock. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $21.00 to $23.00 in a report on Monday, May 12th. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective on the stock. Finally, Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and a consensus target price of $24.13.

Teva Pharmaceutical Industries Stock Down 0.5%

Shares of TEVA stock traded down $0.09 on Friday, hitting $16.67. The stock had a trading volume of 4,823,717 shares, compared to its average volume of 10,269,203. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. The business has a 50 day moving average of $16.72 and a 200 day moving average of $17.40. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $22.80. The stock has a market cap of $19.12 billion, a price-to-earnings ratio of -14.50, a price-to-earnings-growth ratio of 0.86 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same period in the prior year, the firm posted $0.48 EPS. Teva Pharmaceutical Industries's quarterly revenue was up 1.9% compared to the same quarter last year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently made changes to their positions in TEVA. Principal Financial Group Inc. increased its position in shares of Teva Pharmaceutical Industries by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 92,471 shares of the company's stock valued at $2,038,000 after buying an additional 2,752 shares during the period. IFP Advisors Inc increased its holdings in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after acquiring an additional 1,960 shares during the period. Bank of New York Mellon Corp lifted its stake in Teva Pharmaceutical Industries by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 1,621,344 shares of the company's stock worth $35,734,000 after purchasing an additional 67,571 shares in the last quarter. QRG Capital Management Inc. boosted its holdings in Teva Pharmaceutical Industries by 3.9% in the 4th quarter. QRG Capital Management Inc. now owns 148,138 shares of the company's stock valued at $3,265,000 after purchasing an additional 5,556 shares during the period. Finally, Williamson Legacy Group LLC grew its position in shares of Teva Pharmaceutical Industries by 1.7% during the 4th quarter. Williamson Legacy Group LLC now owns 57,824 shares of the company's stock valued at $1,274,000 after purchasing an additional 979 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Insiders Place Their Bets

In related news, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president now directly owns 9,989 shares in the company, valued at approximately $170,012.78. This represents a 38.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.55% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.